Scientists have developed a groundbreaking antivenom leveraging antibodies from Tim Friede, who has undergone hundreds of snake bites. This therapy shows effectiveness against venoms from 19 species, including the king cobra. Coupling traditional pharmacological agents with novel immune responses, this method diverges significantly from current antivenoms that typically rely on animal sources. While researchers express hope for improved treatments, they also highlight ethical dilemmas surrounding Friede's self-experimentation, cautioning against replication of his dangerous practices. This innovative approach could redefine snakebite treatment, emphasizing a need for modern methods over traditional animal-based practices.
The innovative antivenom created using antibodies from Tim Friede targets venoms from 19 deadly snake species and offers a promising alternative to existing treatments.
Researchers emphasize that relying on self-exposure to venom for antivenom development presents ethical issues and must not be replicated by others.
Kartik Sunagar points out that modern immunology tools should replace outdated animal-based methods for antivenom production, enabling broader protection against venomous snakes.
Co-author Jacob Glanville reassures the public that the research team had no involvement with Tim Friede's risky experiments, advocating for safer antivenom development.
Collection
[
|
...
]